MARIIA IVANOVA, transl. Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. KIDNEYS, [S. l.], n. 4.18, p. 36, 2021. DOI: 10.22141/2307-1257.4.18.2016.84326. Disponível em: https://kidneysjournal.com/index.php/journal/article/view/137. Acesso em: 16 mar. 2026.